Curatis Holding AG publishes Annual Report of the (then still named) Kinarus
Group for FY2023 and announces appointment of Chief Financial Officer

Curatis Holding AG / Key word(s): Annual Results/Personnel
Curatis Holding AG publishes Annual Report of the (then still named) Kinarus
Group for FY2023 and announces appointment of Chief Financial Officer

24-May-2024 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc announcement pursuant to Art. 53 LR

  * Full Annual Report of Kinarus Therapeutics Holding AG for the financial
    year 2023 published today

  * Publication of audited consolidated & statutory FY2023 financial
    statements of Kinarus Therapeutics Holding AG already occurred on 17
    April 2024

  * Patrick Ramsauer appointed as Chief Financial Officer of Curatis Holding
    AG with immediate effect

Liestal, Switzerland, 24 May 2024: Curatis Holding AG (CURN.SW), previously
Kinarus Therapeutics Holding AG (together with its subsidiaries "Curatis
Group", or the "Company"), a SIX Swiss Exchange listed specialty
pharmaceutical and therapeutic drug development company focused on orphan
and ultra-orphan indications today published its annual report for FY2023.
The audited consolidated FY2023 financial statements and the audited
statutory FY2023 financial statements of the Company, together the audited
"FY2023
Financial Statements", had already been published on 17 April 2024. Both,
Kinarus Therapeutics Holding AG and its 100% subsidiary, Kinarus AG in
Liquidation had filed for bankruptcy in October 2023, but on 5 February
2024, bankruptcy of Kinarus Therapeutics Holding AG was revoked by the
competent courts of Basel-Stadt to pave the way for the business combination
of Kinarus Therapeutics Holding AG and Curatis AG, a Basel-Landschaft
incorporated specialty medicine distribution and drug development company
(the "Business Combination"), which was completed on 26 April 2024. Kinarus
AG in Liquidation remains in liquidation. The 2023 Annual Report of Kinarus
Group therefore does not provide a comprehensive and transparent picture on
the effective situation of the Company today after the completion of the
Business Combination of Kinarus Therapeutics Holding AG with Curatis AG.

Furthermore, the Company announced today that it has appointed Patrick
Ramsauer as Chief Financial Officer in a part time role with immediate
effect.

Patrick Ramsauer has a strong finance background and has extensive
experience from various financial roles, in Corporate Finance at UBS AG, as
founder of RBR Capital, an asset management company focused on Swiss and
European Equities, in Business Development for Palantir, a US AI and Data
Technology company as well as in his role as CFO of an emerging data
integration technology company since 2021. Patrick Ramsauer holds a Masters
degree in Finance from the University of Zurich, Switzerland. Since spring
2023 he is a Partner at Yuma Capital, a boutique corporate finance & capital
advisory firm, and has in this role amongst others supported Curatis in the
recent business combination with Kinarus. Curatis has found en excellent
candidate to fill this vacant position, and is convinced that Patrick
Ramsauer's knowledge and experience in finance and data technology will
greatly complement Curatis' Executive Management Team.

About the Curatis Group:

Curatis Holding AG is a publicly listed specialty pharmaceutical company
with a distribution and drug development business. The focus of the Curatis
Group's business activities is on high unmet medical need orphan and
ultra-orphan indications, pursued via its wholly owned operating subsidiary
Curatis AG. The Curatis Group was formed by the Business Combination of
Kinarus Therapeutics Holding AG and Curatis AG in April 2024.

Investor Relations Contact:
YUMA Capital
Thomas Bieri
Managing Partner
Tel: +41 44 575 2201
thomas.bieri@yuma-capital.com

Disclaimer
The information contained in this media release and in any link to our
website indicated herein is not for use within any country or jurisdiction
or by any persons where such use would constitute a violation of law. If
this applies to you, you are not authorized to access or use any such
information.
This media release contains "forward-looking statements" that are based on
our current expectations, assumptions, estimates and projections about us
and our industry. Forward-looking statements include, without limitation,
any statement that may predict, forecast, indicate or imply future results,
performance or achievements, and may contain the words "may", "will",
"should", "continue", "believe", "anticipate", "expect", "estimate",
"intend", "project", "plan", "will likely continue", "will likely result",
or words or phrases with similar meaning. Undue reliance should not be
placed on such statements because, by their nature, forward-looking
statements involve risks and uncertainties, including, without limitation,
economic, competitive, governmental and technological factors outside of the
control of Curatis Group, that may cause Curatis' business, strategy or
actual results to differ materially from the forward-looking statements (or
from past results). For any factors that could cause actual results to
differ materially from the forward-looking statements contained in this
media release, please see our listing prospectus in connection with the
Business Combination. Curatis Group undertakes no obligation to publicly
update or revise any of these forward-looking statements, whether to reflect
new information, future events or circumstances or otherwise. It should
further be noted that past performance is not a guide to future performance.
Persons requiring advice should consult an independent adviser.
The information contained in this media release is not an offer to sell or a
solicitation of offers to purchase or subscribe for securities. This media
release is not a prospectus within the meaning of the Swiss Financial
Services Act nor a prospectus under any other applicable laws.
Some financial information in this media release has been rounded and, as a
result, the figures shown as totals in this media release may vary slightly
from the exact arithmetic aggregation of the figures that precede them.


---------------------------------------------------------------------------

End of Inside Information

---------------------------------------------------------------------------

   Language:       English
   Company:        Curatis Holding AG
                   Weierweg 7
                   4410 Liestal
                   Switzerland
   ISIN:           CH1330780979
   Listed:         SIX Swiss Exchange
   EQS News ID:    1910239

End of Announcement EQS News Service
---------------------------------------------------------------------------

1910239 24-May-2024 CET/CEST